Clinical Trial: A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma

U.S., May 13 -- ClinicalTrials.gov registry received information related to the study (NCT07579208) titled 'A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma' on May 06.

Brief Summary: To find the best method of administering NK cells in patients with recurrent glioblastoma.

Study Start Date: Oct. 24, 2026

Study Type: INTERVENTIONAL

Condition: Phase 1 NK Cell IL13Ra EGFRvIII Chimera Antigen Receptor (CAR) NR3C1 Recurrent Glioblastoma

Intervention: DRUG: NK Cells

Given by Ommaya Reservoir

DRUG: NK Cells

Given by IV

Recruitment Status: NOT_YET_RECRUITING

Sponsor: M....